Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2021-04-05 Sale | 2021-04-05 8:17 pm | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 11,864 | $140.19 | $1,663,156 | 19,457 (Direct) | View |
| 2021-04-01 Sale | 2021-04-02 6:00 pm | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 8,925 | $136.47 | $1,218,003 | 31,321 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-08-18 Option Award | 2023-08-21 4:19 pm | N/A N/A | Aurinia Pharmaceuticals Inc. | AUPH | Smith Karen L. Director | 46,872 | $0 | 46,872 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-14 7:02 pm | N/A 2033-06-13 | Talaris Therapeutics Inc. | TALS | Smith Karen L. Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-01 Option Award | 2023-06-05 4:52 pm | N/A 2033-05-31 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 41,650 | $0 | 79,850 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-02 6:35 pm | N/A 2033-01-31 | Quince Therapeutics Inc. | QNCX | Smith Karen L. Chief Medical Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-13 6:16 pm | N/A 2032-06-08 | Talaris Therapeutics Inc. | TALS | Smith Karen L. Director | 14,501 | $0 | 14,501 (Direct) | View |
| 2022-05-19 Option Award(A) | 2022-05-27 5:37 pm | N/A N/A | Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer | 170,354 | $0 | 194,690 (Direct) | View |
| 2022-05-24 Disposition | 2022-05-26 5:26 pm | N/A N/A | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 79,645 | $5.6 | 0 (Direct) | View |
| 2022-05-24 Disposition | 2022-05-26 5:26 pm | N/A N/A | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 173,517 | $0 | 0 (Direct) | View |
| 2022-05-19 Option Award | 2022-05-23 8:24 pm | N/A 2032-03-27 | Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer | 1,541,584 | $0 | 1,541,584 (Direct) | View |
| 2022-05-16 Option Award | 2022-05-17 6:15 pm | N/A 2032-05-15 | Talaris Therapeutics Inc. | TALS | Smith Karen L. Director | 29,002 | $0 | 29,002 (Direct) | View |
| 2022-02-25 Option Award | 2022-03-01 5:14 pm | N/A 2032-02-24 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 37,500 | $0 | 63,200 (Direct) | View |
| 2021-11-19 Equity Swap | 2021-11-22 09:09 am | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 1,622 | $0 | 0 (Direct) | View |
| 2021-11-19 Disposition | 2021-11-22 09:09 am | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 22,932 | $0 | 0 (Direct) | View |
| 2021-06-10 Option Award | 2021-06-14 6:27 pm | N/A 2031-06-10 | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 48,542 | $0 | 128,187 (Direct) | View |
| 2021-06-10 Option Award | 2021-06-14 6:27 pm | N/A N/A | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 25,452 | $4.42 | 128,187 (Direct) | View |
| 2021-05-07 Tax Withholding | 2021-05-11 4:30 pm | N/A N/A | Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer | 305 | $60.85 | 11,888 (Direct) | View |
| 2021-04-05 Exercise | 2021-04-05 8:17 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 2,050 | $52.99 | 19,457 (Direct) | View |
| 2021-04-05 Exercise | 2021-04-05 8:17 pm | N/A 2027-11-15 | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 8,925 | $0 | 19,457 (Direct) | View |
| 2021-04-05 Exercise | 2021-04-05 8:17 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 1,875 | $41.64 | 19,457 (Direct) | View |
| 2021-04-05 Exercise | 2021-04-05 8:17 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 5,000 | $35.34 | 19,457 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 6:00 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 2,050 | $52.99 | 31,321 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 6:00 pm | N/A 2027-11-15 | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 8,925 | $0 | 31,321 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 6:00 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 1,875 | $41.64 | 31,321 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 6:00 pm | N/A N/A | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 5,000 | $35.34 | 31,321 (Direct) | View |
| 2021-02-25 Option Award | 2021-03-01 9:05 pm | N/A 2031-02-24 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 24,600 | $0 | 42,100 (Direct) | View |
| 2021-02-24 Option Award | 2021-02-26 5:15 pm | N/A N/A | Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer | 5,883 | $0 | 23,958 (Direct) | View |
| 2021-02-24 Option Award | 2021-02-26 5:15 pm | N/A 2028-02-23 | Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer | 11,765 | $93.49 | 23,958 (Direct) | View |
| 2021-01-29 Option Award | 2021-02-02 6:52 pm | N/A 2031-01-29 | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 4,844 | $0 | 7,783 (Direct) | View |
| 2020-06-11 Option Award | 2020-06-15 9:15 pm | N/A 2030-06-11 | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 58,246 | $0 | 112,439 (Direct) | View |
| 2020-06-11 Option Award | 2020-06-15 9:15 pm | N/A N/A | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 30,220 | $2.73 | 112,439 (Direct) | View |
| 2020-05-18 Option Award(A) | 2020-06-03 4:30 pm | N/A 2030-05-17 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 30,000 | $0 | 37,500 (Direct) | View |
Ownership | 2020-05-28 7:35 pm | N/A N/A | Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer | 0 | $0 | 18,929 (Direct) | View |
| 2020-05-18 Option Award | 2020-05-20 5:21 pm | N/A 2030-05-17 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 17,500 | $0 | 25,000 (Direct) | View |
| 2020-01-22 Option Award | 2020-01-24 7:32 pm | N/A 2030-01-22 | ACCELERON PHARMA INC | XLRN | Smith Karen L. Director | 9,562 | $0 | 11,124 (Direct) | View |
| 2019-06-13 Option Award | 2019-06-14 5:51 pm | N/A 2029-06-13 | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 46,729 | $0 | 70,702 (Direct) | View |
| 2019-06-13 Option Award | 2019-06-14 5:51 pm | N/A N/A | ANTARES PHARMA INC. | ATRS | Smith Karen L. Director | 23,973 | $2.92 | 70,702 (Direct) | View |
| 2019-06-10 Option Award | 2019-06-12 5:09 pm | N/A 2029-06-09 | SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director | 17,500 | $0 | 22,500 (Direct) | View |